DCT

2:26-cv-11612

IBSA Institut Biochimique SA v. Ascent Pharma Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-11612, D.N.J., 09/11/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey based on Defendant Camber’s principal place of business in the state, Defendant Hetero’s North American marketing office in the state, and Defendants’ business activities and previous litigation history within the district.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's Tirosint® (levothyroxine sodium) capsules constitutes an act of infringement of a patent covering stable pharmaceutical formulations.
  • Technical Context: The lawsuit concerns pharmaceutical formulations for sensitive active ingredients, such as hormones, where stability is critical to ensuring proper dosage and shelf-life, a key consideration in both branded and generic drug manufacturing.
  • Key Procedural History: The action arises under the Hatch-Waxman Act, triggered by Defendant Ascent’s filing of ANDA No. 221008 with a Paragraph IV certification. This certification asserts that U.S. Patent No. 12,564,565, which is listed in the FDA’s Orange Book for Tirosint®, is invalid, unenforceable, or will not be infringed by the proposed generic product. The complaint was filed within the 45-day statutory window following Plaintiff's receipt of Defendants' notice letter.

Case Timeline

Date Event
2023-09-29 '565 Patent Priority Date
2026-03-03 '565 Patent Issue Date
2026-08-26 Date of Defendants' ANDA Notice Letter to Plaintiff
2026-09-11 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,564,565 - Stable Pharmaceutical Formulations of Amino Acids, Peptides or Proteins

  • Patent Identification: U.S. Patent No. 12,564,565, "Stable Pharmaceutical Formulations of Amino Acids, Peptides or Proteins," issued March 3, 2026. Compl. ¶24

The Invention Explained

  • Problem Addressed: The patent's background section describes the problem of chemical degradation in drugs that have an amino acid, peptide, or protein structure, such as levothyroxine (T4) (’565 Patent, col. 1:41-45). This degradation can be accelerated by oxidative processes, which are often catalyzed by metal impurities present in pharmaceutical excipients like glycerin (’565 Patent, col. 1:35-37). The patent suggests that simply controlling for some impurities, such as aldehydes, is insufficient to guarantee stability (’565 Patent, col. 1:59-63).
  • The Patented Solution: The invention is a pharmaceutical formulation that uses a specially purified glycerin as an excipient. The solution, as described in the abstract and detailed description, requires the glycerin to have both a very low iron content (≤0.2 ppm) and a very low content of aldehyde and/or ketone species (≤5 ppm) (’565 Patent, abstract; ’565 Patent, col. 2:22-32). The patent posits that controlling both of these specific impurity types at these low levels is critical to ensuring the stability of the active ingredient (’565 Patent, col. 2:27-32).
  • Technical Importance: This approach provides a method for creating stable liquid or soft-gel formulations for chemically sensitive drugs, potentially improving shelf life and therapeutic consistency (’565 Patent, col. 2:5-11).

Key Claims at a Glance

  • The complaint asserts infringement of claims 1-11 of the '565 Patent Compl. ¶33
  • Independent Claim 1 recites a stable pharmaceutical composition comprising:
    • An active ingredient that is L-thyroxine (T4)
    • Glycerin having ≤0.2 ppm iron and ≤5 ppm aldehyde and/or ketone species
    • Wherein the glycerin is of vegetable origin
  • Independent Claim 8 recites a process for preparing a stable pharmaceutical composition comprising the step of:
    • Combining L-thyroxine (T4) with glycerin having ≤0.2 ppm iron and ≤5 ppm aldehyde and/or ketone species
    • Wherein the glycerin is of vegetable origin
  • The complaint also asserts dependent claims 2-7 and 9-11, which add further limitations such as the presence of water or the specific form of the composition (e.g., oral solution, soft capsule) (’565 Patent, col. 4:11-26).

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendant Ascent’s proposed generic levothyroxine sodium capsules, identified in connection with ANDA No. 221008 ("Ascent's Product") Compl. ¶11 Compl. ¶27

Functionality and Market Context

Ascent's Product is a proposed generic version of Plaintiff's Tirosint® oral capsules, intended to be sold in the same dosage strengths Compl. ¶1 Compl. ¶27 The complaint alleges that the ANDA filing contains data asserting the bioequivalence of Ascent's Product with Tirosint® Compl. ¶28 As this is an ANDA litigation, the infringement analysis concerns the product that Defendants seek FDA approval to market, rather than a product already on sale Compl. ¶33 The complaint does not contain specific details about the excipients or manufacturing process of Ascent's Product, as these are typically confidential elements of an ANDA filing that become known to the plaintiff only through discovery.

IV. Analysis of Infringement Allegations

The complaint alleges infringement under 35 U.S.C. § 271(e)(2)(A), which defines the submission of an ANDA for a drug claimed in a patent as an act of infringement. The core of the allegation is that the product for which Defendants seek approval, if commercially manufactured and sold, would infringe the asserted claims Compl. ¶33 The complaint does not provide a detailed, element-by-element infringement analysis.

'565 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
an active ingredient that is L-thyroxine (T4) Ascent's Product is a generic levothyroxine sodium capsule, which contains L-thyroxine. ¶27 col. 2:13-14
and glycerin having: ≤0.2 ppm iron, and ≤5 ppm aldehyde and/or ketone species The complaint alleges that the composition of Ascent's Product, as detailed in its ANDA, will meet this limitation upon commercial manufacture. ¶33 col. 4:8-9
wherein the glycerin is of vegetable origin. The complaint's general infringement allegation implies that the glycerin in Ascent's Product will be of vegetable origin, as required by the claim. ¶33 col. 4:10

Identified Points of Contention

  • Evidentiary Question: The central dispute will be factual: does the glycerin in the formulation described in Defendants' confidential ANDA filing actually meet the claimed purity requirements of ≤0.2 ppm iron and ≤5 ppm aldehyde/ketone species? The complaint makes a legal conclusion of infringement, but the factual basis for this conclusion will be a primary focus of discovery.
  • Technical Question: A potential point of contention may be the methodology used to measure impurity levels. The patent specification discloses certain analytical methods, such as a DNPH assay (’565 Patent, col. 3:11-18). The case may raise the question of whether Defendants' quality control testing methods and results for their glycerin are consistent with the standards set by the patent.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

  • The Term: "glycerin having ... ≤0.2 ppm iron, and ≤5 ppm aldehyde and/or ketone species"

    • Context and Importance: This limitation defines the point of novelty and is the core of the invention. The entire infringement analysis will likely depend on whether Defendants' proposed product is found to contain glycerin meeting these precise numerical limits.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: A party might argue that the claim language is clear on its face, requiring only that the glycerin meets the specified parts-per-million thresholds, irrespective of the specific analytical technique used, as long as it is a scientifically accepted method. The specification refers generally to "conventional analysis methods" (’565 Patent, col. 2:58-62).
      • Evidence for a Narrower Interpretation: A party could argue that the claim terms should be understood in the context of the specific examples and test methods disclosed in the patent. The specification describes using atomic absorption spectroscopy for iron and a dinitrophenylhydrazine (DNPH) assay for aldehydes/ketones (’565 Patent, col. 2:60-62; ’565 Patent, col. 3:11-18). The experimental data supporting the claimed stability is based on these methods, which might suggest that these are the required standards for measuring infringement.

  • The Term: "stable pharmaceutical composition"

    • Context and Importance: Practitioners may focus on this term because defendants in pharmaceutical cases often argue that such functional language is indefinite under 35 U.S.C. § 112 if the patent does not provide an objective standard for determining what "stable" means.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation (Plaintiff-friendly): A plaintiff would likely argue that the term is defined by the claim itself: a composition is "stable" for the purposes of the claim if it is made with the specified ultra-pure glycerin. The stability is an intended result of the composition, not a separately required feature to be proven for infringement.
      • Evidence for a Narrower Interpretation (Defendant-friendly): A defendant might argue that the specification provides a concrete, objective definition of "stable." The patent's experimental data demonstrates that using the claimed glycerin results in a T4 reduction of ≤5% under specific stress conditions (’565 Patent, col. 4:40-44). A defendant could argue that this functional requirement is part of the definition of "stable," and that infringement requires proof that the accused product achieves this specific level of stability.

VI. Other Allegations

Indirect Infringement

The complaint includes allegations of contributory and induced infringement under 35 U.S.C. §§ 271(b) and (c) Compl. ¶34 The factual basis for contributory infringement is the allegation that Ascent's Product is "especially adapted" for an infringing use and has "no substantial non-infringing use" Compl. ¶35 The basis for inducement would presumably be that Defendants, by seeking to market the product with its FDA-approved label, would be instructing and encouraging physicians and patients to use the allegedly infringing formulation.

Willful Infringement

The complaint does not use the term "willful infringement," but it does request a finding that the case is "exceptional" and seeks attorneys' fees under 35 U.S.C. § 285 Compl. ¶38 Compl. Prayer for Relief ¶E The basis for this claim is not detailed, but in an ANDA context, it often relates to the contention that the defendant's Paragraph IV certification was baseless or that litigation conduct was improper. The defendants' knowledge of the patent is established by their filing of the Paragraph IV certification itself Compl. ¶29

VII. Analyst’s Conclusion: Key Questions for the Case

  1. A Central Factual Question: The case will primarily turn on a question of compositional identity to be resolved in discovery: does the formulation described in Defendants' confidential ANDA for their generic levothyroxine capsules utilize a glycerin excipient that, in fact, contains ≤0.2 ppm iron and ≤5 ppm aldehyde/ketone species? The outcome of the case hinges on the answer to this factual, evidence-based question.

  2. A Key Claim Construction Question: A core legal issue will be one of definitional scope: is the term "stable pharmaceutical composition" defined simply by the use of the claimed ingredients, or does it incorporate a functional requirement tied to the specific stability performance (≤5% degradation) demonstrated in the patent's examples? The court's answer will determine whether Plaintiff must only prove the composition of Defendants' product or also prove its performance under stress testing.